ãªããžã§ãªãŒã«ãã¹ ã¬ãã¥ãŒãšåºåã®åè§£
ãããªã¯ ãã¯ã¿ãŒã»ãã¯ã¿ãŒã®éšåã«å§ãŸã "ãã®æ ç»"ã®æ åã§ã ãªãºã·ã§ãŒ. "ãµã€ãšã³ã¹ã»ãã"ãšããåã®ç·ã 2çš®é¡ã®äººå·¥èèªã æã«æ±ããŠããã 宿䞻ããã¯è ¹ã®è...
8,226+
Videos & Ads
+50-100
Fresh Daily
$29.90
Per Month
Full Access
12.5 TB database · 72+ niches · 27 min read
ãããªã¯"Dr. ãªãºã·ã§ãŒ* "ãµã€ãšã³ã¹ã»ãã"ãšããåã®ç·ã æã« 2çš®é¡ã®äººå·¥èèªã æã£ãŠããŸã äž»äººå ¬ã¯è ¹ã®è質ã 人æ°ä¿¡å¿µã«åã㊠æãç°¡åã«æžã£ãŠãããšèª¬æããŠããŸã ã¢ãã«èèªã«ç²æ«ã泚ãèŸŒã¿æ¶²åããŸã. æŒåºã¯åå Žçãªãã®ã§ã äœæ°ãªãã§ã ãŸã,äœéæžå°è£çµŠååžå Žã§æµéããŠããããè€éãªãããªè²©å£²æžç°¡ (VSLs) ã®1ã€ãžã®å ¥éç¹ã§ããããŸã. ãã©ã³ãå [Lipo Jelly]/blog/reviews/lipo-jelly-review-vsl-analysis-gelatin-trick-weight-lossãšããŠçºå£²ããã ** LipoJellyCapsã®ã»ãŒ"æééã®ãããã§ã. ãããªãçµãããš,åæ³çãªãã¬ãçªçµããåããæ åãçµã¿ç«ãŠãŸãã. å®åšã§çºæãããæåäººã®æ¯æè ã«ãã䞻匵ã§ã. GLP-1ãšGIPãã«ã¢ã³ãå«ã詳现ãªè¬åŠæ©æ§ããã,6ã€ã®ããŒãã¹ããžã¿ã«è£œå,2åã®æœéžè³åããã³60æ¥éã®éè¿æžä¿èšŒã®ãªãã¡ãŒã®æ§é ããããŸã. ãã¹ãŠã¯Mounjaro泚å°ã®æé¡äŸ¡æ Œ $2,000 ã«åºã¥ããŠããŸã. ãã®äœåã¯ååã®èšŒèšã§ã è§£éã§ããªã. åæçãªèªã¿åãã§ã ãã®äž»åŒµã¯ã©ã®ããã«èª¬åŸåã®ããåœ¢ã§æ§ç¯ãã,ãã®åºç€æåç§åŠãå®éã«æ¯æããŠããããšãæœåšçãªè³Œå ¥è ãè¡åããåã«ç¥ã£ãŠããã¹ãããšã. ãªã³ããžã§ãªãŒã«ãã¹ã¯2ã€ã®åŒ·åãªåžå Žåã®äº€å·®ç¹ã«äœçœ®ããŠããŸã:GLP-1代æ¿åãžã®ã¢ã¯ã»ã¹æ§ã®é«ããªãŒã ãã¯åŸã®æ¶è²»è ã®é£¢ããšãµããªã¡ã³ãæ¥çã«ãããç©æ¥µçãªçŽæ¥å¿çããŒã±ãã£ã³ã°ã®é·ãäŒçµ±ã§ã. 補åãã©ã®ããã«æ©èœãããçè§£ããããšã¯,補åã®æ¯åŠããè©äŸ¡ããããšãšåããããéèŠã§ã. VSLã®æ žå¿è«ç¹ã¯æ§é çãªãã®ã§ãã. è¥æºã¯è¡åé害ã§ã¯ãªã,é£ç©äŸçµŠæ¯çŽ ã«ãããã«ã¢ã³æ¬ é¥ã§ãã,ãã®æ¬ ä¹ããã¥ã³ãžã£ããåæçã«å¯ŸåŠããæ ¹æ¬åå ã§ãããšäž»åŒµã,ãŒã©ãã³ã®åºãæãã¬ã ããµããªã¡ã³ãã§ã¯ã¢ãŠã³ãžã£ãŒããŒã®åéGLP-1ãš GIP掻æ§åã«èªç¶ã§ããå®ãå¯äœçšãªãã§è€è£œã§ãããšãã䞻匵ã§ã. ãããã®äž»åŒµã¯ããããç°ãªã蚌æã®è² æ ã䌎ã. çç©åŠã®åºç€ã¯ ãããã®ããããŸã 蚌æ ãããã¯ããã«è¶ ããããæœåºç©ããããŸã. 3ã€ç®ã®ã«ããŽãªãŒã«ã¯ åœé ãããæ¿èªãèªåŒµããçµ±èšã𠿥æ§çãªä»çµã¿ãå«ãŸããŸã ãã®ç®çã¯èŠèŽè ããããã®è³ªåãèãã®ã«ååãªæéãæ¢ããªãããã«ããããšã§ã ãã®åæã§èª¿ã¹ãããåé¡ã¯ åçŽã§ã ç§åŠã¯ã©ãã§æ¢ãŸã,販売ãå§ãŸãã®ã? ãªããžã§ãªãŒã«ãã¹ãšã¯äœã.æ¶è²»è ã«åãããããã©ã³ãåã§ãããªããŒãªãŒã®äžã«çœ®ãã®ã 35æ³ä»¥äžã®å¥³æ§ã«äž»ã«å£²ãããŠããã¬ã è£œã®æ é€è£å©å€ã§ãã,åºå·çãªäœèèªãèœãšãããšããŠããã®ã§ã. ãã®è£œåã¯,ãªãŒã³ã㯠(ã»ãã°ã«ãŒãã) ãšã ãŒãŠã³ãžã£ã (ãã£ã«ããã¿ã€ã) ã®ãããªæ³šå°è¬ãåæçã«å°å ¥ãããã«ã¢ã³ãšåãäœå ã§çç£ãåºæ¿ããŠãããšäž»åŒµããŠãã"倩ç¶GLP-1掻æ§å€"ã®æ¥éã«æ¡å€§ããã«ããŽãªãŒã«äœçœ®ããŠããŸã. æ ŒåŒã¯? è åãç²æ«,ãŸãã¯æ»Žã®ä»£ããã«ã¬ã ã§ã. 粟床é éã¡ã«ããºã ãšããŠç޹ä»ãã, VSL ã¯é·ç¶ãã§ãŽã ã improvised home recipes ããäžè²«ããæäžãæäŸãããšäž»åŒµããŠããŸã. 補åã¯, VSL ã«åºã¥ããŠç±³åœã§FDAã«ç»é²ãã GMPèªèšŒãåããæœèšã§è£œé ãããŠãã,èªç¶ååç©å°éã®ç¬ç«ããæ¥æ¬ã®å»è¬åäŒç€Ÿã§ããNotori LabsãšããäŒæ¥ãšååããŠäœæãããŠããŸã. 掻æ§åæåã¯6ã€ã®ã³ã¢ã³ã³ããŒãã³ãã«äžå¿ã§ãã.çŽç²ãªãŒã©ãã³ (æ°šé žã°ãªã·ã³ãšã¢ã©ãã³ã®æºæ³) æ¥æ¬ç·è¶ã®æœåºç©,氎溶æ§ã³ãã²ã³ã¿ã€ã1 ãã¿ãã³C ã¢ã»ãã©ã®æ¡ããã«ã¡ãªãã¯ããã³ãã€ããªã³ã§ã. ãããã®æåã¯,äžè¬çãªå¥åº·è£çµŠåã§ã¯ãªã äœéå¢å ã®ãã«ã¢ã³åå ãæšçãšããèšåºçã«æ ¡æ£ãããã·ã¹ãã ãšããŠé 眮ãããŠããŸã. ååã¯ç¬èªã®è²©å£²ããŒãžãéããŠã®ã¿å£²ãã,å°å£²ãã£ã³ãã«ã第äžè ã®ããŒã±ãããã¬ã€ã¹ã§å©çšã§ããªã. 察象ãšãªããŠãŒã¶ãŒã¯,çŽ35æ³ãã65æ³ã®å¥³æ§ã§ ãã§ã«åŸæ¥ã®æžéæ¹æ³ (ãã€ãšãããéåããã°ã©ã ãªã©) ãèžãŸããŠãããæç¶çãªçµæãåºãªãã,泚å°å¯èœãªGLP-1è¬ã®å¯äœçšãèªèããŠãããã®ã®è² æ ã¯ã§ããªãããªã¹ã¯ãè² ãææ¬²ããªã. VSL ã®èšèªã¯,ãã®ãããã£ãŒã«ã«æ£ç¢ºã«æºæ ãã,ã¿ãŒã²ãããŠãŒã¶ããã§ã«çµéšãã倱æã¢ãŒããç¹°ãè¿ãåœåã,ããããŠãŒã¶ãŒã®è¡åã§ã¯ãªã,ãªããžã§ãªãŒã«ãã¹ãä¿®æ£ããããã«èšèšãããã·ã¹ãã çãªãã«ã¢ã³æ©èœé害ã«é¢é£ä»ããŠããŸã. ## ç®æšã®åé¡ã¯ ãªããžã§ãªãŒãã£ããã¹ã®äœéæžå°åžå Žã¯æ¬åœã«å·šå€§ã§æ¬åœã«äžæºã§ã. äžçè¥æºé£ç㯠2030幎ãŸã§ã« å šäžçã®10å人以äžã è¥æºã§æ®ãããŠãããšäºæž¬ããŠããŸã ç±³åœ ã® çŸç ã³ã³ãããŒã« ãšäºé²ã»ã³ã¿ãŒ (CDC) ã¯,çŸåš ã¢ã¡ãªã« 人 æäººã® çŽ 42% ãè¥æº ã« ãªã ããš ã èŠ ãŠ ãã.ãã® æ°å㯠éå» 40 幎 é æ¥æ¿ã«å¢å ã ã ãã® ã§ã. ããã¯èæ§çãªçµ±èšã§ã¯ãªã, äŒçµ±çãªé£äºãéåã«ãã 人å£èŠæš¡ã§ã®ä»å ¥ã«æµææ§ã®ããçŸå®ã衚çŸãã€ã€ãã ãã®åå ã®éžæçè§£éã§ãã£ãŠã VSL ãæ£ç¢ºã«èгå¯ããŠããäºå®ã§ã. VSL ã¯,ãã®æµè¡ã®åå ãç¹ã«2ã€ã®ã€ã³ã¯ã¬ãã³ãã«ã¢ã³GLP-1 (ã°ã«ã«ãŽã³ã®ãããªããããâ1) ãš GIP (ã°ÙÙÚ©ãŒãºäŸåæ§insulinotropic polypeptide) ã®æ¬ ä¹ãšããŠå®çŸ©ã,è¶ å å·¥é£åæ·»å ç©ãä¿åå€ã«ãã£ãŠäœå ã®èªç¶ãªè·ã«ááçç£ã劚ãããã. ãã®æ çµã¿ã¯ç§åŠçãªéšåçã«æ¯æãããŠããŸã. GLP-1ãšGIPã¯,飿¬²ã®å¶åŸ¡ããã³ä»£è¬æ©èœã«ããã圹å²ãèšåºæç®ã§ããèšé²ãããŠããçã®é£œåæ§ãã«ã¢ã³ã§ãã. ã»ãã°ã«ãŒãã (Ozempic, Wegovy) ãšå GLP-1/GIP ã¢ãŽãã¹ããã£ã«ãŒãã¿ã€ã (Mounjaro, Zepbound) ã®ãããªGLP1å容å€ã¢ãŽã³ã·ã¹ã¿ã®åçãªåæ¥çæåã¯è¬åŠã¬ãã«ã§çç©åŠçã¡ã«ããºã ãæ€èšŒãã. çŸä»£çãªé£äºãã¿ãŒã³ãå çã€ã³ã¯ã¬ãã³åæ³ãæãªãå¯èœæ§ããããšããäž»åŒµã æ£åœãªç ç©¶åéã§ã. VSLãè¶ ãããš,ãã®å ææ§èª¬æã®ç¹ç°åºŠã§ã. "æ·»å ç©,ä¿åç©è³ªãé ãããæ¯çŽ ã®éå°æå"ã 99.9%ã®äººå£ã§ GLP-1ãšGIPãçç£ããæ¹æ³ã äœç³»çã«åæãããšãã䞻匵㯠èšèã«ããæœåºã§ããæ¢å®ãªçºèŠã§ã¯ãããŸãã. è žå æ³åŠæç®ã®å®éã®ã€ã¡ãŒãžã¯ããªãè€éã§ã ã€ã³ã¯ã¬ãã³åå¿ãåäœ,éºäŒåŠ,è é埮çç©çŸ€æ§æ,é£äºç¹ç¶æåé,é£ç©ã®çµæãšèåãªã©ã«ãã£ãŠç°ãªããŸã. æŠæ¬ãããš "ããªãã®å€±æã¯ ããªãã®ãããããªã" ãšããææ çãªãããã㯠VSL ã®ç©èªãšã³ãžã³ã«é§åããã®ã§ãã ããã¯ç°è³ªãªççåŠççŸå®ã äžã€ã®æªåœ¹ãžãšåçŽåããŸã ãã€ãªã³ã¯åãæ¥çã§,ãã®è£œåããªããžã§ãªãŒãã£ãã¹ã«ä»£ããäŸ¡æ Œã§ã. > ãã®æžéãããã®ä»ã® VSLs ã¯ã©ã®ããã«åœŒãã®ããŒããæ§æããŠããã®ãäžæè°ã§ãã? èªã¿ç¶ããŸã [第7ç¯]#å¿ççèªçºãšèª¬åŸçç¥) ã¯äžèšã®äž»åŒµã®èåŸã«ããå¿çåŠãåè§£ããŸã. ## ãªããžã§ãªãŒãã£ãã¹ã®ä»çµã¿ VSL ãææ¡ããã¡ã«ããºã ã¯,æ¬ç©ã®è¬åŠçãªæŽå¯ã«åºã¥ããŠãã,蚌æ ãè£ä»ãããã®ä»¥äžã«åºãã£ãŠããŸã. çã®éšå:GLP-1ãš GIPã¯äž»ã«è žå L现èãK现èã«ãã£ãŠé£ç©æåã«åå¿ããŠæŸåºãããã€ã³ã¯ã¬ãã³ãã«ã¢ã³ã§ã. è ¹è ã®ç©ºããé ãã㊠ã€ã³ã¹ãªã³åæ³ã«åºæ¿ãäžã ã°ã«ã³ãŒã¹äŸåã,éèŠãªåœ¹å²ãæãããŸã. ååãªã«ããªãŒæåéããããšã,貯èµãããèèªããšãã«ã®ãŒã®ããã«åããããã«èº«äœã«ä¿¡å·ãéã. Mounjaro (ãã£ã«ãŒããã) ã¯,äž¡å容äœã«å¯ŸããŠåéã¢ãŽãã¹ããšããŠèšèšããããã,èšåºäœéæžå°è©Šéšã§ã¯ä»¥åã®GLP-1-ã®ã¿è¬ãããåªããæ§èœãçºæ®ããã. VSL ã¯ãã®è¬çåŠçè«çãæ£ç¢ºã«èšè¿°ããŸã. ææ¡ãããèªç¶ã¡ã«ããºã ã¯ãŒã©ãã³ã®2ã€ã®ã¢ããé žã«åºã¥ããŠããŸã. ã°ãªã·ã³ãš ã¢ã©ãã³; VSL ã®äž»åŒµã§ã¯,è žå ç¥çµäŒéç©è³ªãšããŠæ©èœã,ãšã³ãã²ãŒãGLP-1ããã³ GIPçç£ãåºæ¿ããå容äœã掻æ§åãããããšãã§ããŸã. åŒçšãããå ·äœçãªæ°å (ã°ãªã·ã³ãGLP-1ã182%å¢ãã,ã¢ã©ã³ã€ã³ã¯144%ã® GIPãå¢ãã) ã¯åœç«å»åŠå³æžé€šããã®çºèŠãšããŠæç€ºãããŠããŸã. ãããVSLã®äžã§ç¹å®ã§æ€èšŒå¯èœãªå ¬è¡šç ç©¶ã«å±ããŠããŸãã. æ£åœãªç ç©¶ããç¥ãããã®ã¯,ç¹å®ã®ã¢ããé ž ç¹ã«çŽ°è žã®ã¿ã³ãã¯è³ªæ¶åäžã«æŸåºãããæ°šåºé žã¯ã€ã³ã¯ã¬ãã³åæ³ãåºæ¿ãããšããããšã§ã.ããããéšåçã«é«èçœè³ªãªé£äºã§ã¯ é«çæ°ŽçŽ ãèèªãå€ãé£ããã ååãªã«ããªãŒãå«ãã§ããé£ã¹ç©ãã匷ã飜åä¿¡å·ãäœãããŸã. ã°ãªã·ã³ã¯ç¹ã«ã€ã³ã¹ãªã³æææ§ãšä»£è¬å¥åº·ã®èгç¹ããç ç©¶ãããŠãã (Alves et al., British Journal of Nutrition, 2019),ããã,GLP-1ãç¹å®ã®å²åã§äžæãããèœåãã¬ã ãµããªã¡ã³ãã«å«ãŸããå¯èœæ§ã®ããæäžéã«ãããŠåé¡ã¬ãã¥ãŒãããæç®ã§ã¯ç¢ºç«ãããŠããªã. "ã¢ããé žãäžæ§ã®æŽ»æ§ãåºæ¿ãã"ãã",ç ã£ãŠããéã«ã§ã 24æéèèªççŒã®åãã åŒãèµ·ããã¬ã ã€"ã«åŒããš ãã®ä»çµã¿ã¯åççãªçç©åŠãã販売ã³ããŒãžãšå€ãããŸãã ãªã³ããžã§ãªãŒã«ãã¹ã ã ã³ãžã£ããã"93å匷åã "ãšãã䞻匵ã¯,è£ä»ããåããªãã ãã§ãªã,衚é¢çã«ã¯è¬åŠçãªæç®ãšççŸããŠãã. ãã£ã«ãŒãããã®äœéæžå°å¹æ (SURMOUNT-1詊éšã«ãã3æè©Šéšã«ãããå¹³åäœééã®20%ã22%æžé) ã¯,ãã®åéã§ã®è¬åŠçä»å ¥ã¯ä»åã®äžéã衚ããŠããŸã. ã©ã³ãã åå¶åŸ¡è©Šéšã§ã¯ èªç¶è£çµŠåã ãã®æ°åã«è¿ã¥ããŠããªã. æ¯èŒã¯èšèª¬çã«æ©èœã ç§åŠçã§ã¯ãªã. ##ããŒæåãšæ§æèŠçŽ ãã®6ã€ã®çµæç©ã¯,ããã€ãã®ç°ãªãççåŠçæ©èœãèŠã. 2ã€ã¯ æ žãã«ã¢ã³æ©æ§ã察象ãšãã 1ã€ã¯ ã€ã³ã¹ãªã³å¶åŸ¡,1ã€ã®ãç®èã®æŽäœæ§,ãã1ã€ãè žçã«æšçãã. ãã¶ã€ã³è«çã¯ããŒã±ãã£ã³ã°ã¢ãŒããã¯ãã£ãšããŠäžè²«æ§ããã,補åã®äž»èŠãªäž»åŒµãå¯äœçšãªã¹ã¯ (ç®èã®è»åŒ±) ãšãšã€ãšãŒãªãã³ãºåé¡ã«ã€ããŠé åºçã«æ±ããŸã. ä¹³ç³åœ¢åŒã®èšåºçšéãåŒçšãããç ç©¶ã§äœ¿çšãããã®ãšäžèŽãããã©ãã㯠VSL ã®ã ãã§ç¥ããŸãã. - çŽç²ãªã²ã©ãã³ (ã°ãªã·ã³ãšã¢ã©ã³ã€ã³),ãžã§ã©ãã³ã¯ã³ã©ãŒãŒã³ã®ç±æ¥ã§æ°Žååã¿ã³ãã¯è³ªã§ã. ã°ãªã·ã³ã¯æãè±å¯ã«ããã¢ããé žã§ ãŒã©ãã³ã®æ°šåºé žå«éã®çŽ25%ãå ã ã¢ã©ã³ã€ã³ãæ¿åºŠããäœãå Žåã«ååšãã. VSLã¯ãããã®æ©èœãè žå ç¥çµäŒéç©è³ªãšã㊠GLP-1ãšGIPã®çç£ãåºæ¿ãããšäž»åŒµãã. 代è¬å¥åº·ã«ãããã°ãªã·ã³ã®åœ¹å²ã¯,èšåºåããã³äžéšã®ããç ç©¶ã§æ¯æãããŠããŸãã,è£çµŠçšéã®éã«ã€ã³ã¯ã¬ãã³æŽ»æ§å广ãç¹å®ããããšã¯æç®ã§ã¯æªå®å šã«ç¹åŸŽã¥ããããŠããŸã. - æ¥æ¬ç·è¶æœåº (EGCG),ã°ãªãŒã³ãã£ãŒå ã®äž»èŠãªçç©æŽ»æ§ã«ããã³ã®ãšãã¬ãã±ãã³ã®ã£ã©ãŒã (EGCG),人éã®è©Šéšã«ãããŠèèªé žåãšinsulinæææ§ã®ããããªæ¹åã«é¢é£ä»ããããŸãã. åœéè¥æºèª ã§ å ¬éããã 2009 幎 ã® ã¡ã¿ ã¢ããªãžã¹ã¯,ç·è¶ ã«ããã³ã äœéé ãšè °åšãã® äžå° ã« ã€ã ㊠å°ãã ã æ°åŠ ç 㪠ãã® ã 瀺ã ã ããš ã¯æãã ã§ã. VSL ã®äž»åŒµã¯,ãã®æœåºç©ãæåãã女æ§ã§ã¯"è ¹ã®èèªéã2åãæžã£ã"ãšç ç©¶ãç¹å®ããã« American Journal of Clinical Nutrition ã«åç §ããŠãã. ãã®äž»åŒµãææžåããã广ãµã€ãºã«é倧è©äŸ¡ãããŠããããã§ã. - ã¿ã€ã1æ°Žååã³ã©ãŒã²ã³,æ°Žååã³ãã¬ã³ã®ããããã¯åžåæ§ãè¯å¥œã§,ç®è³ªåŒŸæ§ããã³æ°Žååãæ¹åããã®ã«æå¹æ§ã瀺ããã©ã³ãã ãªå¶åŸ¡è©Šéšäžã§ã. ç®èè¬åŠã»ççåŠã®è«æãå«ã.* (Proksch et al., 2014). VSLã«ã¯,ãã®æåãå«ãŸããŠãã. ç¹ã«"Ozempic face"ãªã¹ã¯ãé²ãããã§ã. ç®èã®ç·©ã¿ãã§è¿ éãªäœéæžå°ã«äŒŽãè¡ãããŸã. ããã¯æ£åœãªæžå¿µã§ãã,ãã®å«ãã¯æŠç¥çã«äžè²«ããŠãã.ããã,280ãã³ã以äžã®äœéæžå°ã§ã³ã©ãŒã²ã³ãšãšã©ã¹ãã£ã³ã®çç£é6åå¢å ã䞻匵ããJAMAåŒçšã¯ç¹å®ã®æ€èšŒå¯èœãªç ç©¶ã«è¿œåã§ããªãã** ã¢ã»ãã©ã®æ¡ããåŸããããã¿ãã³C*ã§ã. ã¢ã¹ã³ã«ãã³é žã¯ã³ã©ãŒã²ã³ã®åæã«ãããŠäžå¯æ¬ ãªå ±åèŠå ã§ãã,æ°Žååã³ãã©ã²ã³ãçµåãããããšã¯ççåŠçã«åççã§ã. ã¢ã»ãã©ãã§ãªãŒã¯ãã¿ãã³Cã®å€©ç¶ã«å¯ãã ãã®ã§ã. çµã¿åããã¯ç§åŠçã«åççã§,æåããªã¹ã¯äœã. - [ã«ãã](/ããã° /ã¬ãã¥ãŒ/ã«ãã-ããã©ã€ã»ãããŒããªãã¯-ç·æ§åŒ·åvslåæ) (ã¯ã«ã¯ãã³) ã«ã«ãã¥ãã³ã¯,ã«ã¡ãªã¯ã®äž»èŠãªçç©æŽ»æ§ååç©ã§ãã,NF-κBçççµè·¯ãæå¶ããææžãå«ãåºç¯ãªæçºç±ç ç©¶ããããŸã. åžæ¶ã®èª²é¡ã確ç«ãã,ãããªã³äœµçšã«ãã£ãŠçã«è§£æ±ºãããŠããŸã. åŒçšãããæ°å;ãããªã³ã®çç©å©çšæ§ã®2000%ã®æ¹å,ã·ã§ãçã«ããç ç©¶ (1998幎) ãåç §ãã (Planta Medica, 1998),ããã¯å®æ çã§é »ç¹ã«åŒçšãããŠããç ç©¶ã§ã¯å¹æãæ¯èŒçå°ãããã詊éšããçºçãè žå ãã«ã¢ã³å容äœãžã®é©çšã¯æœåºã§ãã. - Piperine (Black Pepper Extract) ,ã«ãªãã¥ãã³ã¯ããªã«ã«ã«ãã€ãªã¢ã¯ã»ã·ããªãã£ãé«ããäœçšã§ ãutraseuticalã«ããããã確ç«ããã¡ã«ããºã ã®äžã€ã§ã æåŠã«ã€ããŠã§ã. è£çµŠå€ãšããŠç§åŠçã«æ£åœåãããŠãã. VSLã®é瀺æ²ã¯"ãªããã®å¥åŠãªãŒã©ãã³ããªãã¯ãæ¯æ¥1ç«æ¹ã ãé£ã¹ãããšã§,ã¬ãã«ã»ãŠã£ã«ãœã³ã¯ãã€ãšãããéåããããšãªã,5ã€ã®å¥œããªé£åãã諊ããªãã ãã§ããã68æ¥ã§77ãã³ãç©ããã®ã?"ãšãã顿ã§ã.ãšãŒãžã³ã»ã·ã¥ã¯ããã4段éãŸãã¯5æåžå ŽçãªæŽç·Žãããåããšåé¡ããæç§æžäŸã§ãã. äœéæžå°ã®èŠ³å®¢ã¯ äœå幎ãã®éçŽæ¥çãªå©ç ("30æ¥éã§ 30ãã³ããèœãšã") ãš ã¡ã«ããºã (ã¡ã¿ããªãºã ã«ãã®å¥åŠãªããªãã¯ã§åºæ¿) ã®äž»åŒµã飜åããŠããŸãã. 2024幎ãŸã§ã« ãã®ã«ããŽãªã®äžå€®æ¶è²»è ã¯ çŽæ¥çãªãããããã¹ãŠèŠãŠãã,ããã«åŒ·ãæçè«ãçºæ®ããŠããŸã. çŽæãç¹å®ã§ååã®é«ãæåçã«éŠŽæã¿ã®ããæå人ã®ç©èªã®äžã«åã蟌㿠ããã䞻匵ã§ã¯ãªã質åãšããŠåãäžããããšã§ ãã®äž¡æ¹ãåé¿ããŸã ãã®ããšã奜å¥å¿ã®ã®ã£ãããçã¿åºããŸã (Loewenstein,1994), èªè ã¯ãŸã çããç¥ããªãã®ã§,ãã®ã®ã£ãããéããããšããæ¬²æ±ã¯ çŽæ¥çãªè£œå䞻匵ãæåŠããæ¹å€çãã£ã«ã¿ãŒãäžåããŸã. ããã¯ã¯ãŸã第äºã®æ©èœãæãããŸã. ãã®äººç©ãå®éã«æ¿èªããå¿ èŠãªãã«,ç¥ãããå ¬çãªäººç©ã®æš©åšãåããŸã. ã¬ã¹ãã«ã»ãŠã£ã«ãœã³ã®å ¬çãªäœéæžå°ã®æ ã¯å®åšããŠãã,ãã®æ è¡ã VSL ã®ç¹å®ã®è£œåã«é¢é£ä»ããããšã¯æ€èšŒã§ããªãã,ã»ãŒééããªãæé ãããŠãã. ããã é¢é£ã¯èгè¡ã®æçè«ãçºèŠããåã« æåã®æã§ç¢ºç«ãããŸã. ããã¯çŽæ¥å¿çã³ããŒã©ã€ã¿ãŒãã¡ã"halo transfer"ãšåŒã¶ãã®ã®äžçš®ã§ã æ¢ç¥ã®ååã«ä»ããŠããããžãã£ããªé¢é£ã¯è²©å£²ãããŠãã補åã«åœ±é¿ããŸã ããåºãåºåã¢ãŒããã¯ãã£ã¯,ããé·ãAIDAæ å ã«åã蟌ãŸãã *Problem-Agitated-Solution (PAS)æ§é ã à° à°šà±à°žà°°à°¿à°à°à°¿ãã,ã¢ã¬ããŒã·ã§ã³ãšãœãªã¥ãŒã·ã§ã³ã®æ®µéã®éã«ã¯é°è¬å°èª¬ãæ¿å ¥ãã,ãªã解決çãåºãå©çšã§ããªãã®ãã説æããŸã. ããã¯è€éãªæ§é çãªåãã§ã. é°è¬ã®ç©èª (è£œè¬æ¥çããã®çºèŠãåãã) ã¯åæã«åé¡ã匷ã,åé¡ã«å¯ŸããŠå é§ãã«å察ãã (ãªãç§ã以åã¯èããããšããªãã£ãã®ã?) ãšèšãã,çå®ãäŒããããã«å人çãªãªã¹ã¯ãåãåæ°ããå éšäººç©ãšããŠå£²ãæã眮ãã®ã§ã. X4/>: - "ãã®ç²æ«ã¯ã ã³ãžã£ãã®åœ±é¿ãåãç¶ãã§ããã®ã«93åã匷åã "ãšèšãããŠããŸã. (æ¯èŒæ ) - "æ¯æ¥ãªãŒã³ãã¯ã泚å°ãããããªæ°åã ãå¯äœçšã¯ãŒã" (åå ¥ãããè¬ã®æ ªåŒ) - "è£œå€æ¥çã¯ãã®åžå Žã«äœå¹Žãæãç¶ããŠãã" (é°è¬æ¶æ§) - "Mounjaroã®éçºã§åŒçšããç ç©¶ã«ãããš,ããã¯å¯èœã ãšç€ºã",ãããé ãããšã«æ±ºãã" (æå¶ãããç宿¶ãç©) - "121,300人以äžãæ¢ã«èªåèèªççŒãéå§ããŠãã" (瀟äŒèšŒæ é) ** MetaãŸãã¯YouTubeãã¹ãã®ããã®åºåæšé¡å€ç°: - "å»è ã¯,ã¢ãŒã³ãžã£ããã§ããªãããšãããã²ã©ãã³ãèŠãããªã" - "æã®ã¬ã ãã¯35æ³ä»¥äžã®å¥³æ§ã«ãªãŒããã¯ã·ã§ãããå ¥ãæ¿ãã" - "ç§åŠè ãã¡ã¯é£å ãžã§ã©ãã³ã®2ã€ã®ã¢ãã³é žãçºèŠã èèªççŒãã«ã¢ã³ã1æ©ã§æŽ»æ§åããã" - "ã¬ãã«ã»ãŠã£ã«ãœã³ã¯ããã«ãã£ãŠ77ãã³ãã倱ã£ã. è¬æ¥ç㯠ãã®ãããªãåããããã« äœçŸäžãã®ãéãæããŸãã "ãã®åç»ã®"ã€ã®äŸã, è£çµŠåã®ã«ããŽãªãŒã§ã¯,説åŸåã®ãã建ç¯ã¯ç°åžžã«æŽç·ŽãããŠããŸã. ãã®"x4/> ã®é åçãªæ§é ã¯,ãµããªã¡ã³ãéšéã«ç¹åãããã®ã§ã. åäžã®è§Šçºæ©ã䞊è¡ããŠå±éãã代ããã« ãã®è£ã«èšŒèšããã, ãã®èŸºã§äžè¶³ã®éç¥ãããã®ã§ VSL ã¯æš©åšãåªå€±å«æªæãã¢ã€ãã³ãã£ãã£è åšã»èªç¥äžå㚠瀟äŒèšŒæãæå³çã«ç©ã¿éããé£ç¶ã®äžã§ å 匷ããŸã. åå±€ã¯ åæ¹ã«ãããã®ã匷åããŠããŸã. ã·ã¢ã«ãã£ãã¯ã«ã¿ãã°ãèªèãã. ã·ã§ã¯ãã㯠ãã®ã·ãŒã±ã³ã·ã³ã°ã ã³ããŒã¹ã©ã€ã¿ãŒã®ä»äºã ãšèªèããŸã 圌ã¯,äœéæžå°æ¶è²»è ã®ããã«æŽç·Žãããåžå Žã ã©ããªåççãªè°è«ãçéžããåã«ææ çãã¬ããŒããå¿ èŠã§ããããšãçè§£ããŠããŸã. ãªãŒããã³ã°ã®ãã¯ã¿ãŒã»ã¹ã€ã«ã... ãªãºæ§åŒã®ã㢠ã¬ã¹ãã«ã»ãŠã£ã«ãœã³æ¶ãæµãè ãã«ã¢ã³ã¡ã«ããºã 説æãšè¬å€é°è¬ç©èªã¯ å¥ã ã®èŠçŽ ã§ã¯ãªã èŠæ¹ãèŠæ¹ã®å¥œå¥å¿ããèå¥ãž æ£çŸ©çãªæããžãšåæ©ã¥ããããè¡åã«ç§»ãããã® ã·ã³ã°ã«ã®ãšã¹ã«ã¬ãŒããã¬ãŒã ã圢æããŸã é°è¬ã®è£æã¯æ§é çãªè£ 眮ãšã㊠ç¹ã«æ³šç®ã«å€ãã. è¬æ¥çãæªåœ¹ãšç§°ã㊠ãã¯ã¿ãŒã»ãã¯ã¿ãŒã«ã«äœçœ®ã¥ããŸãã ããŒã¯ã»ãã€ãã³ (Mark Hyman) ã¯,ãã£ãªã¢ããªã¹ã¯ã«ãããããšããçå®ã®èªãæãšã㊠VSLã¯ãã§ã¹ãã£ã³ã¬ãŒ (1957) ã"èªç¥äžåææžå°""ãšè¡šçŸãããã®ã掻æ§åããŸã. 芳è¡ãé°è¬æ ãåãå ¥ããäžæŠ,ãã®è£œåãæçµ¶ããããšã¯æµåŽã«ãããããªæèŠã§ã. è²·ããªãããšã¯,åãªã忥çãªéžæã§ã¯ãªãé埳çã«è² è·ã®åŒ·ãéžæè¢ã«ãªããŸã. ããã¯æ®éã®èª¬åŸãè¶ ããŠå€§ããªãšã¹ã«ã¬ãŒã·ã§ã³ã§ãã,èŠèŽè ã®ã¢ã€ãã³ãã£ãã£ãæ€æ°ãããŸã. - ã»ã¬ããã£ã»ãœãŒã·ã£ã« 蚌æ (Cialdini,1984幎): åä¹±è ãŠã£ã«ãœã³ã®å€é©ã¯ç©èªã®ã¢ã³ã«ãŒãšãªã; ãªãŒã¹ã»ãŠã£ã¶ãŒãºããŒã³ãæçš¿ãã Instagram èšäº,ãªãã©ã®çãã®ãã玹ä»ãã±ãªãŒã»ã¯ã©ãŒã¯ãœã³æ°ã®æªç¥é¢é£ãš RFKãžã¥ãã¢ã®èšè äŒèŠã§æåäººã®æš©åšãè€æ°ã®ç¹ã§æããŠãã. 广ã¯çŽ¯ç©æ§ã§ã:èŠèŽè ã1ã€ã®æ¿èªã«å¯ŸããŠæççãªå Žåã§ã,ååã®æ°åã®èšå€§ãªéã¯å ±æãéžãåºããŸã. - æå€±å«æªãšäººå·¥çšæ (ã«ããã³&ããŽã¡ãŒã¹ããŒ,1979): VSLã®éã«ããã«æ°å€ã¯72ãã26ã«äœäžãã. åŸ ã¡åããã®ãªã¹ãã¯200äžäººã . ãã®æ°å㯠å®éåãã å人çã«èšå®ãããæéãšããŠæ©èœã,ããŒãžãéããæ ããªãã®ç¹å®ã®ã¹ãããã¯æ¶ããŸã. ããã¯æå€±å«æªãæŠåšã«ãããã®ã§ã 倱ãããšãžã®çã¿ã¯è¡åã«ããæœåšçãªå©çãããçã ããã®ã§ã - æš©åšç§»è»¢ (Cialdiniã®æš©éåå): ã. ããŒã¯ã»ãã€ãã³ã®æ¬è³ªã¯ æ£åœãªæ©é¢ã§ åœŒã®æ¬ã¯æ¬ç©ã®ãã¹ãã»ã©ãŒã§ã 粟å¯ã«èšè¿°ãã ç§åŠçãªæ ¹æ ã®ãªã䞻匵ã®çºå°å°ãšããŠäœ¿çšãããŸã æ¬ç©ã®å±¥æŽæžã®ä¿¡é Œæ§ã¯ åœé ããã䞻匵ã«è¿äŒŒæ§ã«ãã£ãŠç§»è»¢ããŸã. ããã¯æã广çã§æŽ»åããåèšãããæš©åšã§ã. - ãšããã¡ããŒããªããž / æ ¹æºåæ§æ (ãã«ã³ãœã³): VSL ã®æãéèŠãªæ§é çãªåãã¯,以åã®äœéæžå°å€±æã¯ãã¹ãŠåœŒãã®ã³ã³ãããŒã«å€ã®äœãã«ãã£ãŠåŒãèµ·ããããŠãããšèŠèŽè ã«çŽåŸãããã®ã§ã (ãã«ã¢ã³æ¬ ä¹çãè¬å€æå¶) ããè¡åã§ã¯ãããŸãã. ãã®åæ§æã¯ååã販売ããã ãã§ãªã,è³Œå ¥è ã®å人å²ãåæžãåºãããšã§è£œåã ããè«ççãªçµè«ãšãªã. - æ å ±ã«ããäºææ§ (Cialdiniã®çžäºæ§): GLP-1,GIP,ã°ãªã·ã³ããã³ã¢ã©ã³ã€ã³ã«é¢ããæ¡åŒµèª¬æ. ç§åŠçãªå¯å€§ãã§æäŸãããŸãã. è² åµæãæããã®ã§ã. èŠèŽè ã¯,䟡å€ããã€ã³ãµã€ããŒç¥èãç¡æã§åãåã£ããšæããŠãã,ããã¯å¿ççã«è³Œå ¥ã«ãã£ãŠå ±åŸ©ããããä¿ããŠãã. - ãšã³ãã£ã³ã°å¹æãšãŒããªã¹ã¯ãã¬ãŒã (ã¿ã©ãŒ,1980): 60æ¥éä¿èšŒã¯"ç§ã¯ã€ãšã¹ãæ±ããªãã",ãã ããããã ã"ãšããŠæç€ºããããã®ã§ãã,ãã®è¡šçŸã§ã¯è²·åãæ°žä¹ çãªæ±ºå®ã§ã¯ãªãé転å¯èœãªè©Šç®ãšèŠãªãããšã§ã³ãããã¡ã³ãã®ç²Ÿç¥çéãã軜æžããŸã. - ã¢ã€ãã³ãã£ãã£è åšããã³ã¹ããŒã¿ã¹é¡æ:" VSLã¯,äœãµã€ãºã«ã€ããŠç¹°ãè¿ãæ¥ãèªçºãã ("è¢ã®ã·ã£ãã®äžã«é ã"",é¡ããé ãã" "倫ã®ç®ã«ã¯æ¬²æãæ ã") ãããŠãã®åŸã«ç¶æ å埩ã®ããã®ã¡ã«ããºã ãšããŠè£œåãæäŸããŸã. ããã¯ãŽãã£ã³ã® (2008) éšæè«çã«åŸã£ãŠ,補åãè£å®ã§ã¯ãªã"æçµçã«ãããçè§£ãã女æ§ã³ãã¥ããã£ã®ã¡ã³ããŒãšããŠäœçœ®ã¥ããããŠããŸã. " > ãããã®æŠè¡ã¯50+ VSLs ã§ã©ã®ããã«æ¯èŒãããŠãããèŠããã§ãã? æš©åšã®äœ¿çšã¯è€æ°ã®ã«ããŽãªãŒã«åãããŠããŠ,åå¥ã®è©äŸ¡ã«å€ããŸã. ãã®2ã€ã®åéã§ã¯,ãã®é åãç°ãªããã®ãšããŠå®çŸ©ãããŠããŸã. åæ³çãªçµããã«: ã. ããŒã¯ã»ãã€ãã³ã¯æ¬ç©ã®å»è ã . ããµãã¥ãŒã»ããå·ã¬ã³ãªãã¯ã¹ã«ãã圌ã®è¶ å¥åº·ã»ã³ã¿ãŒã¯ æ©èœçãªå»çã¯ãªããã¯ã§ã åœŒã®æ¬ã¯"è¡ç³æº¶æ¶²""èèªãé£ããã "",氞幎è¥è "ã¯ãã¥ãŒãšãŒã¯ã¿ã€ã ãºã®ãã¹ãã»ã©ãŒã§ã. å士ã®åºæŒã¯... ãªãº,CBS This MorningãšTEDããŒã¯ãèšé²ãããŠããŸã. ãã®äºå®ã®æ ¹æ ã¯å®åšã§ãã,ä¿¡é Œæ§ã®é«ã蚌æ ãæäŸãããŠããªã䞻匵ãå«ããã¹ãŠã®çµæã«æå³çã«ä¿¡çšæ§ã®ããã¢ã³ã«ãŒãšããŠäœ¿çšãããŸã. å士ã®ããŒãžã§ã³ã¯,x4/>ã§ã. ããããã€ãã³ã¯ çã®ãã¯ã¿ãŒã»ãããªã®èšèãåŒçšããŠããŸã. ããã²ãã ã»ã«ãã¹ã«ã€ã㊠Hyman ã¯ å ¬ç¶ãšèªã£ãŠããŸããã,å®éã®Dr. Hyman ã¯ãã®è£œåã«é¢äžããŠããã,ãŸãã¯ãã®èº«åãåæãªãã«äœ¿çšãããŠãããã©ããã«ã€ããŠã§ã. ããã¯ãµããªã¡ã³ã VSL ã«ããŽãªãŒã§äžå®ã«ããè¿ããããªã£ãæ £è¡ã§ãã. ç§åŠçãªåŒçšã¯ ãªã¢ã«ãšæé ããããã®ãæ··ããé¡äŒŒã®ãã¿ãŒã³ã«åŸããŸã. ç®ããªã³ã¯ ã«ã«ãã¥ãã³ã® çäœå©çšãæå€§2000%åäžããããšãã䞻匵ã¯,å®éã®ç ç©¶ããåŸãããŸã. "åç©ãšäººéã®ãã©ã³ãã£ã¢ã«ãããã«ã«ã³ãã³è¬å€ã®æŽ»æ§åã«å¯Ÿãããã€ããŒãªã³ã®åœ±é¿" (Shoba et al., 1998幎) Planta Medicaã§ã. äœéæžå°ã«ããããã«ãŒãã¿ã€ãã®æå¹æ§ã確ç«ããSURMOUNT-1詊éšã¯, New England Journal of Medicine (Jastreboff et al., 2022) ã§çºè¡šãããå®ã®ç ç©¶ã§ã. GLP-1ãšGIPãé£œåæ§ããã³ä»£è¬æ©èœã«ããã圹å²ã¯,è¬åŠçã«ç¢ºç«ãããŠãã. ãã®çã®ã¢ã³ã«ãŒã¯ VSLã®ç§åŠçç©èªã«ä¿¡é Œæ§ã®è³ªãäžã çºæãããèŠçŽ ãæ€åºããã®ãé£ããããŸã. ããã,çºèŠã®ç©èªã®äžå¿ã§ãããžã§ã©ãã³ãéã㊠GLP-1ãšGIPãèªçºçã«æŽ»æ§åãããèæœ°çã§æ£ã£ã4æ³ã®æ£è ã®"2018幎ã®ã¹ã¿ã³ãã©ãŒãç ç©¶"㯠æ€èšŒå¯èœãªå ¬è¡šããã調æ»ã«è¿œåã§ããªã. ç¹å®ã®çŸåæ¯äž»åŒµ (GLP-1ã¯ã°ãªã·ã³ã«ãã£ãŠ182%å¢å ,GIPãã¢ã©ã³ã€ã³ã«ãã144%äžæ) ã¯åŒçšå¯èœãªæ å ±æºãªãã§æç€ºãããŠããŸã. é£äºãéåã®ã¿ãæåãã人ãã"GLP-1ãšGIP ãæŽ»æ§åãã人ã¯67åãäœéã倱ã£ãŠãã"ãšäž»åŒµããŠãã JAMA ã® ç ç©¶ã¯,ãã®çºèŠã«é¢ããJAMA ã«åé²ãããè«æã«äžèŽããŠããªã. ãªãŒã¹ã»ãŠã£ã¶ãŒãºããŒã³ Instagram ã®æçš¿ã¯ ã»ãŒç¢ºå®ã«äœè£œãããŠããŸã. ãžã¥ãã¢ã®å ±éçºè¡šã¯ ã¢ãŠã³ãžã£ãã«å¯ŸãããŒã©ãã³ãæ¯æãã ãšãã蚌æ ã¯ãªã. æäŸ,äŸ¡æ Œèšå®ããã³ãªã¹ã¯é転ã¯,å®éã®åžå Žã«ããŽãªãŒåºæºã§ã¯ãªã ææ çãªæ¯èŒè ã«å¯ŸããŠå€ã®åºå®åã®ããå®è¡ãããäŸã§ã. åºæ¬çãªæ¯æ±ã¯,å¹³åè£çµŠäŸ¡æ Œ (äœéæžå°ã«ããŽãªãŒã§ã¯$30-60/ããã«) ã§ãªã Mounjaroã®æé¡è²»çš $2,000ã§ã. åŠæ¹è¬ã§ å»åž«ã®é¢äž,ä¿éºç®¡çãš 2é±éã«1åã®æ³šå°ãå¿ èŠã«ãªããŸã. æã¬ãžãã«ã®è£å å€ã$49泚å°è¬ã«åºå®ããããšã¯ æ£åœãªã«ããŽãªãŒæ¯èŒã§ã¯ãããŸãã. ããã¯è£œåãå®éã«æäŸãããã®ã«é¢ä¿ãªã,äŸ¡æ Œã¯è謬çã«æå©ãªããã«èŠãããããªèšèª¬çãªè£ 眮ã§ã. "顧客ã1ç¶ã§ $700 ãæäŸãã"ã¯,æ€èšŒå¯èœãªæ ¹æ ã®ãªãæé ãããæ¯èŒã§ãã. éå±€äŸ¡æ Œæ§é (ãããã$49 6ç¶,å3å $69 2å $79) ã¯æšæºçãªçŽæ¥å¿çæ £ç¿ã«åŸããŸã. æå€§ã®ãã³ãã«ã¯ååŒããšã«æãåçãåããäžæ¹ æãå¯å€§ãªäº€æã§ããããã«èŠãã. 6ã€ã®ããŒãã¹ããžã¿ã«è£œåã¯,売ãæã«ãšã£ãŠéçã³ã¹ããä»å ãã,èŠããã䟡å€ã®ç©ã¿éããå€§å¹ ã«èšåŒµããã. æœéžè³ (ã®ãªã·ã£ã®äŒæ,ã»ãã©ã©ã®ããã«ãŒã,ãã«ãã³ã°ãã«ã® ã®ããã«ãŒã) ã¯å€ãã®åžæ³ç®¡èœã«ãããŠè³Œå ¥ãªãã§åæ³çã«å©çšå¯èœã§ããå¿ èŠããããŸãã VSLã¯ããããè²·ãæã®ã¿ãšããŠæç€ºã,éå¶ããåžæ³ç®¡èŸåºã«å¿ããŠèŠå¶å¯©æ»ãæ£åœåããããšããããŸã. 60æ¥éã®éè¿æžä¿èšŒã¯ ç³ãåºã®æãæ£åœãªèŠçŽ ã§ã. ååŒã®è²¡åãªã¹ã¯ã軜æžããæå³ã®ããæ¶è²»è ä¿è·ãšããŠ,質åã®ãªã60æ¥éã®è¿æžãŠã£ã³ããŠãæç«ã,ãã®è©äŸ¡ã¯"x4/>ã ãã§ã§ããªã. ä¿èšŒã®èšèª¬çãªæ çµã¿ã¯ "ãã "ãããã"ãšãããã®ã§ã ããã¯å€å žç販売æè¡ã§ãã ãã®è£ã«ããã¡ã«ããºã ãçŸå®ã§ã ççž®ã®äž»åŒµ (72ç¶,幎ã«äžåºŠçç£ãããããã,37,942人ã®åæã«èŠèŽè ) ã¯äºå®äžã®ãã®ã§ã¯ãªãåçãªãã®ã§ããã",æå·¥å"ãããå¶äœã¯æ¢ã«114,000人ã察象ãšãããã®ãšäžäžèŽãããã®ã®,1äž4å人ã«å©çšãããç°å¢ãåµé ã ãã®åœ±é¿ã§è³Œå ¥ããåã«ååãããæ éã«èª¿æ»ããããèªçºã§ããæ€èšãé»å®³ãããã®ãšããæéå§å¶çç°å¢ã« ãªã. ##ããã¯èª°ã®ããã« (ãããŠããã¯èª°ãã§ã¯ãªãã®ã) è¶ 35æ³ä»¥äžã®å¥³æ§ã代è¬å¥åº·ã«æ£åœãª ç§åŠçæ¯æãããæåã䜵çšãã䟿å©ãªæ¥åžžè£çµŠå€ã欲ããã®ã§ã. ãã®é£åã¯,æ é€çŽ ã®æåéã«ã€ããŠéåžžã«é«ãæ°Žæºã§æ©èœããŠããŸã. ããã€ãã®æå (ç·è¶ããEGCG,ãããªã³ãšã«ã«ã¯ãã³,æ°Žååã³ã©ãŒã²ã³,ãã¿ãã³C) ã¯èšåºè©Šéšãããæäžéã§æçã§ããããšã蚌æããŠãã ãããã®æåãé åãããã formulããã¬ã ãããåºç¯ãªå¥åº·çæ³ãåççã«ä¿é²ããããšãã§ãã. 補é ã®äž»åŒµãæ£ç¢ºã§ããå Žå (FDAã«ç»é²ããã,GMPèªèšŒãåããæœèš,å»è¬åã¬ãã«ã®èª¿é) ããã¯å¥åº·ãªæäººã®ã»ãšãã©ã«ãšã£ãŠå®å šã§ã. æ¢åã®å¥åº·ç¿æ £ãè£å®ãããªã¹ã¯äœããµããªã¡ã³ããæ¢ã,ã€ã³ã¯ã¬ãã³ã«æ¯ããããæ é€ã«ã€ããŠèå³ããã人㯠ãã®æåã®ãããã£ãŒã«ã調ã¹ãã¹ããã®ãšãªã广çšåºŠã«ã€ããŠã®çŸå®çãªæåŸ ãæã£ãŠããŸã. è³Œå ¥è ãšããŠã®ç¹åŸŽã¯,æ³šææ·±ãã¢ãããŒããã¹ãã§ã. 3ã¶æä»¥å ã«77ãã³ã 15æ¥ã§29ãã 2åç³å°¿ç ã® 32æ¥åŸã«è»¢ç§»ãæåŸ ãã人ã¯èª°ã§ã æ²»ççµæãäºæ³ãããŸã è£çµŠå€ã®æäžã§æåç§åŠãè£ä»ãããã®ãšã¯äžèŽããªããã,ãããã®å ±åã¯åœé ãŸãã¯åçã«èªåŒµãããŠããããã§ã. æ¢åã®ä»£è¬ç¶æ ãæã€è²·ãæ,ã¯ã«ã¯ãã³ãEGCG (è¡æ¶²ãèãããè¬,ç³å°¿ç å€ãŸãã¯ååŠçæ³ç©è³ªãå«ã) ãšçžäºäœçšããŠããè¬ãæçšããè ããã³åŠåš äžã®å¥³æ§åã¯æ¯ä¹³æç²ŸãããŠãã人ã¯äœ¿çšåã«å»åž«ã«çžè«ããå¿ èŠããããŸã. æãéèŠãªã®ã¯ ãã®ãµããªã¡ã³ãã®å¥œéœåã« GLP-1 è¬ã«ã€ã㊠å»åž«ãç£ç£ããäŒè©±ãæŸæ£ããããšãèããŠãã人éã§ã. > ãã®åè§£ã¯ã€ã³ãã«ãµãŒãã¹,æã ã®ç¶ç¶äžã® VSL 峿žé€šãšåºåã³ããŒåæã®äžéšã§ã. äœéæžå°è£çµŠåã®ã«ããŽãªãŒã§åæ§ã®è£œåãæ¢ããŠããå Žåã¯,èªã¿ç¶ããŸã. ## ããèããã質å Q:ãªããžã§ãªãŒã®ã«ããã¯è©æ¬ºã§ãã? A:補åã®æåã§ããã°ãªã·ã³,ã¢ã©ã³ã€ã³,EGCG,ã¯ã«ã¯ãã³,ã³ã©ãŒã²ã³,ãããªã³ãå®çšçã§å¥åº·æ§ã®ãã忥çã«å©çšå¯èœãªååç©ã§ã. ä¿¡é Œã§ããªãã®ã¯,ç¹å®ã®äœéæžå°çµæ (68æ¥éã§ 77ãã³ããŸã§) ãšäž»åŒµãããããšãæåäººã®æ¯æã®ããã€ãã (ãªãŒã¹ã»ãŠã£ã¶ãŒãºããŒã³æçš¿ã¯åœé ãããŠããããã§ã), ãããŠã ã³ãžã£ããæå¹ãªè¬å€ãæ¯èŒããããšã§ã. ãã®è£œåã¯,ç¡å¹ãªç³é å€ã§ãããšããç¹ã§åœé çã§ã¯ãªããããããŸããã,ãã®è²©å£²ã¯ç§åŠãæ¯æãããã®ãå€§å¹ ã«èªåŒµããŠãã. Q:ãªããžã§ãªãŒã«ãã¹ã®æåã¯äœã§ãã? A: VSLã«ã¯6ã€ã®æŽ»æ§ç©è³ªãèšèŒããŠããŸã:çŽç²ã®ãŒã©ãã³ (ã°ãªã·ã³ãšã¢ã©ã³ã€ã³ãæäŸãã),æ¥æ¬ã®ç·è¶æœåºç© (EGCG) ,ã¿ã€ã1åæ°Žååã³ã©ãŒã²ã³,ãšã»ãã©ã®æ¡ããåŸããããã¿ãã³C, кÑÑкÑãã³ã® (ã¯ã«ã¯ãã³),é»ãããããŒããã®ãããªã³ã§ã. ä¿é·è³æã«ã¯,1åãããç¹å®ã®ããªã°ã©ã ã®éãèšèŒãããŠããªã. Q:ãŒã©ãã³ããªãã¯ã¯æ¬åœã«äœéæžå°ã«å¹æãããã? A:ã°ãªã·ã³ã®ãããªãžã§ã©ãã£ã³ç±æ¥ã¢ãã³é žã¯,ã€ã³ã¹ãªã³æææ§ãšè žãã«ã¢ã³æŽ»åã«å¯Ÿããé©åºŠã«åœ±é¿ãå«ã代è¬äžã®å©ç¹ã«é¢ãã蚌æ ãããã€ã瀺ããŠããŸã. ããã,æ¯æ¥çšãããŒã©ãã³ã¬ã ãMounjaroã®äœéæžå°å¹æãè€è£œãããšãã䞻匵㯠åçŽå¯©æ»ãããèšåºèšŒæ ã«ãã£ãŠè£ä»ããããŠããªã. åç:ãªããžã§ãªãŒã«ãã¹ã«å¯äœçšãããã? A:äžèšã®æåã¯,å žåçãªè£çµŠå€æäžã§å®å šã§ãããšäžè¬çã«èªèãããŠããŸã. é«éã®EGCG (ç·è¶ã®æœåº) ã¯,ç¹ã«ç©ºè ¹ã§æ¿çž®ãããè£çµŠåœ¢æ ãšããŠæåããå Žåã«ãããŠäžéšã®æ£è ã§ã¯èèã¹ãã¬ã¹ã«é¢é£ä»ããããŠãã. ãã€ããŒãªã³ã¯,ç¹å®ã®è¬ç©ã®åžåãé«ã,æå¹ãªæäžéãå€åãããå¯èœæ§ããããŸã. ãã®ãµããªã¡ã³ããæäžããåã«åŠæ¹è¬ã䜿çšãã人ã¯å»åž«ã«çžè«ããå¿ èŠããããŸã. ** çå:LipoJellyCaps ã¯OzempicãŸãã¯Mounjaroãšã©ã®ããã«æ¯èŒãããŸãã? A: farmakologicalã¬ãã«ã§ã¯æå³ã®ããæ¯èŒã¯ãããŸãã. OzempicãšMounjaroã¯èšåºè©Šéšã§äœäœéã®15ã22% ã®å¹³åæžéçµæãèšé²ãããåŠæ¹ãããŠãã GLP-1 å容å€ã¢ãŽãã¹ãã§ãã. LipoJellyCapsã«ã¯ã€ã³ã¯ã¬ãã³æŽ»æ§ããããã«ãµããŒãããæåãå«ãŸããŠããã,ãããã®è¬ã®ã¬ãã«ã§ã®æå¹æ§ã¯èšåºè©Šéšã§ã¯ç¢ºèªãããŠããªã. "93å匷å"ãšãã䞻匵ã¯ç§åŠçæ ¹æ ããããŸãã. ** çå: 50æ³ä»¥éã®ãªããžã§ãªãŒã«ãã¹ã¯å®å šã§ãã?* A: åã ã®æåãäžè¬çã«å¥åº·ãªæäºº50æ³ä»¥äžã§ã¯ãªã¹ã¯ãé«ãã§ã. ãã®å¹Žéœ¢å±€ã«ãšã£ãŠæãéèŠãªæ³šæäºé ã¯,ãããªã³ã®æœåšççžäºäœçšã§ãã ãã®äººå£çµ±èšã«ãããŠäžè¬çã«åŠæ¹ãããè¬å€ã§ããã¹ã¿ãã³ãè¡å§å»è¬åããã³æååºè¬ãå«ã. æ°ããè£çµŠçæ³éå§åã«å»åž«ãŸãã¯è¬å€åž«ã«çžè«ããããšããå§ãã§ã. Q: LipoJellyCaps ã®çµæãèŠãã®ã«ã©ããããæéãããããŸãã? A: VSL è«æ±çµæã¯10æ¥ä»¥å ã«,åçãªå€åã15-30æ¥ã§èµ·ãããŸã. ãããã®æé軞ã¯,æå蚌æ ãè£ä»ãããã®ãšã¯äžèŽããªã. æççããã³ä»£è¬è£å©æåãå«ããµããªã¡ã³ãã¯,éåžž 8-12é±ééã«ããã£ãŠäžè²«ããŠäœ¿çšããå¿ èŠããããŸã.éèŠãªå€åã芳å¯ãããåã«,åã ã®çµæã¯é£äºã掻åã¬ãã«,åºå€å¥åº·çã«å€§ããç°ãªããŸã. Q:ãªããžã§ãªãŒã«ãã¹ã¯æ¬åœã«2åç³å°¿ç ãé転ãããããšãã§ããã? A:ã¿ã€ã 2ã®ç³å°¿ç ãéæ»ãã®ã«æ é€è£å å€ã«é Œãã¹ãã§ã¯ãªãã,ãã®ãããªèœåãæã€ã©ã®ãµããªã¡ã³ããå»ççã«å®çŸ©ãããã¹ãã§ã. 責任ããããšãããªã. è³Œå ¥è ã32æ¥ä»¥å ã«2åç³å°¿ç ãé転ããããšãã VSL ã®èšŒèšã¯,çŸåšã§ã¯ç³å°¿ç å¯è§£ã«é¢ããèšåºççè§£ãšäžèŽããŠããªã. ã¿ã€ã2ç³å°¿ç ã®å¯è§£ã¯ äž»ã«äœéãå€§å¹ ã«æžãã,é£äºç¿æ £ãå€ããããšã æã ããªãªã¯ãªããã¯æè¡ã«ãã£ãŠå¯èœã§ãã å»åž«ã«ãã管çãå¿ èŠã§ã. ç³å°¿ç 蚺æãåãã人ã¯,è£çµŠåã®è²©å£²ã«åºã¥ããŠè¬ãæ²»çèšç»ã倿ŽããŠã¯ãªããªã. ##æçµçãªæçšãªããžã§ãªãŒã«ããã¹ã¯æŽå²çã«è峿·±ãæåç¬éã«å±ã補åã§ã. æäžå¯èœãªGLP-1è¬ã®æ®åã«ãã äœå幎ã«ãæž¡ã£ãŠåã㊠ã€ã³ã¯ã¬ãã³ãã«ã¢ã³ã¡ã«ããºã ãçè§£ã,è¥æºãçç©åŠçãªåºè³ªãæã€ããšãèªããŠããæ¶è²»è ãå¢ã æé¡æ°åãã«ã§ãªã¹ã¯ãè² ãå»è¬åã« ããå®å šãã€å®äŸ¡ãªä»£æ¿åãç©æ¥µçã«æ¢ããŠããŸã. VSL ã¯,ãã®åžå Žãããªãæ£ç¢ºã«èªã¿åããŸã. 3幎åã«äžæã®ãã«ã¢ã³ã§ çŸåšæåã«ãªã£ã GLP-1ãšGIPã äžžããšçµã¿ç«ãŠãããšæ±ºããã®ã¯å¶ç¶ã§ã¯ãããŸãã æ¶è²»è ã®æŽç·Žã å€ãã®ç«¶åä»ç€Ÿãããå ã«é²ãããšãçè§£ãã ã³ããŒã¹ãã£ãŒã¯ããŒã ã®ä»äºã§ã ãã® VSL ããã調ã¹ããš,åæå€æã¯è£œåã確ãã«äžæ£ã§ãããšã¯éããŸãã. ãã®æåã®å€ã㯠æ£åœãªç§åŠãè£ä»ãããã®ã§ 補é ã®äž»åŒµãæ£ç¢ºã§ããã° æå³ã®ãã質ã®é«ãä¿¡å·ã§ã 倿ã¯,è³Œå ¥è ã«å¯ŸããŠæ£ç¢ºãªæåŸ ã圢æã§ãããããªæ¹å€çãªè©äŸ¡ã®ä»æ¹ãé²ãããã« VSL ã®ããŒã±ãã£ã³ã°æ©åšãæ§ç¯ãããŠãããšãã. åœé ãããæåäººã®æ¿èªã远ãã€ããã§ããªãç ç©¶åŒçš "ã ã³ãžã£ããã93å匷"ã®äž»åŒµ 人工çççž®åæ°ãšé°è¬ç©èªã¯ ãã¹ãŠäžã€ã®æ©èœã«ä»ããŸã ããã¯èºèºããç°å¢ãäœãåºãããšã§ãã èªæ¬ºãããæ éããæããã®ã§ã ãã®å»ºç¯ã¯ èåŸã«ãã補åã«é¢ä¿ãªã æçã«åä»ãããã䟡å€ããããŸã. è³Œå ¥ãã人ã®ããã« ãããŸã§ã®èªã¿æ¹: ãããªããžã§ãªãŒã«ãã¹ã®æåã èªåã®æ¡ä»¶ã§èå³ãæ¹ããªã. æççæ§,ã³ã©ãŒã²ã³æ¯æçããã³æœåšçã«ã€ã³ã¯ã¬ãã³èª¿ç¯å€ã®çµã¿åãããšã㊠ãã®é¢å¿ã¯äžåçã§ã¯ãããŸãã. 60æ¥ä¿èšŒã¯ äŒç€Ÿããããå°éãããªã ææçŸ©ãªã»ãã¥ãªãã£ããããæäŸããŸã ããã2é±éæªæºã§ 2æ¡ã®äœéæžå° ã¢ã³ãžã£ãã¬ãã«ã®ãã«ã¢ã³ã®æŽ»æ§å,ç³å°¿ç ãé転ãã ã»ã¬ããªãŒçŽã§ã®èº«äœçå€é©ãçŽæãããå ·äœçãªçµæã¯ èšåºçãªäºæž¬ã§ã¯ãªã ããŒã±ãã£ã³ã°æ§é ãšããŠçè§£ãããã¹ãã§ã. ç§åŠã¯çŸå®ã§ãã 売äžã®èœåãç§åŠã®èšã以äžã®ãã®ãªã®ã§ã ãã®åå¥ã¯ Intel Servicesã®äžéšã§ VSLãš ad-copy ã®åæãç¶ç¶çã«æäŸããŠããŸã. äœéæžå°è£çµŠå€ã倩ç¶GLP-1掻æ§ååšã®é¢é£è£œåã«ã€ããŠèª¿ã¹ãŠãããªã,èªã¿ç¶ããŸããã. ãã®èšäºã§ã¯ç ç©¶ã»æè²ç®çã®ã¿ã§ã. å»ç,æ³åŸ,éèã«é¢ããå©èšã§ã¯ãããŸãã.ãŸã補åã補é è ãšã®é¢é£ããããŸãã. å¥åº· ä¿éº ã éé ã® åé¡ ã« ã€ã ㊠ã¯,åžžã« æèœ 㪠ãããã§ãã·ã§ãã« ãšçžè« ãã.*
Comments(0)
No comments yet. Members, start the conversation below.
Related reads
reviewsBurnSlim VSLãšåºååæ
ãããªè²©å£²ã®éå¹ã®2ç§éã« ããç¹å®ã®ãªããŒãªãã¯ãªè³ãã 眮ãããŠããŸã ã±ãªãŒã»ã¯ã©ãŒã¯ãœã³ã 1 ãã¥ãŒãã®ãŒã©ãé£ã¹ãŠ 68æ¥ã§ 60ãã³ãç©ãããš èŠèŽè ã«äŒããããŠããŸã
Read- DISreviews
ãªã³ããžã§ãªãŒ VSLãšåºååæ
ãããªã¯ããèŠããããã¬ãè£ çœ®ãš ãããã®å®¹åš ãã㊠ã·ãã¥ã¬ãŒã·ã§ã³ãããèèªã æ°Žæ§œã«æº¶ããŠããæ åã§å§ãŸããŸã ãã®åå ŽçãªæŒåºã§ã¯ ãã®ä¿¡é Œæ§ã...
Read
reviewsãªãã»ãã€ã ã¬ãã¥ãŒãšåºåã®åè§£:ç ç©¶ååèŠæ¹
å£²ãææçŽã¯ ã»ãŒæ ç»åãããã·ãŒã³ã§å§ãŸããŸã äžççã«ç¥ãããæå人ã "ãŽã©ãŒã°"ã®ããã¥ã¡ã³ã¿ãªãŒã€ã³ã¿ãã¥ãŒã«åº§ã£ãŠ å€éååŒãèšè¿°ããŠããŸã...
Read